Upload
Featured Recent Articles Topics Login Upload

Search Results for ''

published presentations and documents on DocSlides.

Antiangiogenic Agents in Advanced NSCLC
Antiangiogenic Agents in Advanced NSCLC
by ellena-manuel
Jared Weiss, MD . Assistant . Professor of Medici...
Multidisciplinary approach to lung cancer
Multidisciplinary approach to lung cancer
by elena
Kamil Konopka. Department of Oncology, University ...
Optimizing Nursing Management of Patients Receiving Novel Therapies for Advanced NSCLC
Optimizing Nursing Management of Patients Receiving Novel Therapies for Advanced NSCLC
by southan
Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Pra...
Consensus or Controversy?  
Consensus or Controversy?  
by okelly
Addressing Practical Clinical Questions Across the...
Treatment in Advanced Non-Small Cell Lung Cancer
Treatment in Advanced Non-Small Cell Lung Cancer
by oconnor
. 5. th. most commonly diagnosed cancer in Austra...
Please note, these are the actual video-recorded
Please note, these are the actual video-recorded
by chaptoe
proceedings from the live CME event and may includ...
James Yang,
James Yang,
by pasty-toler
MD. The Evolving Treatment Landscape in NSCLC: Co...
Thierry
Thierry
by cheryl-pisano
Le Chevalier, . MD. The Role of Translational Res...
Optimal treatment for elderly patients with NSCLC
Optimal treatment for elderly patients with NSCLC
by cheryl-pisano
Giorgio V. Scagliotti. University. of . Torino,....
Second line
Second line
by alida-meadow
treatments. in WT . pts. : . which. . opportuni...
Italian cohort of
Italian cohort of
by test
nivolumab. Expanded Access . Programme. (EAP): ...
Please note, these are the
Please note, these are the
by vizettan
actual. . video-recorded proceedings from the . l...
Second line treatments in WT
Second line treatments in WT
by deena
pts. : . which. . opportunities. with . biologic...
Integration of Immunotherapy Across
Integration of Immunotherapy Across
by karlyn-bohler
the Spectrum of Lung Cancer. Karen Kelly, MD. Pro...
Integration of Immunotherapy Across
Integration of Immunotherapy Across
by pamella-moone
the Spectrum of Lung Cancer. Karen Kelly, MD. Pro...
Estimated costs of managing treatment-related adverse
Estimated costs of managing treatment-related adverse
by lindy-dunigan
eventsof. . nivolumab. and . docetaxel. in the...
Low TPS High TPS TPS = PD-L1 tumor proportion score Low TPS = 10%; high TPS = 60%
Low TPS High TPS TPS = PD-L1 tumor proportion score Low TPS = 10%; high TPS = 60%
by olivia-moreira
Low TPS High TPS TPS = PD-L1 tumor proportion sco...
Lung cancer Treatment
Lung cancer Treatment
by attentionallianz
Consequences of the Lack of Patients of color &...
Module 13: Targeted Treatment
Module 13: Targeted Treatment
by disclaimercanon
of Lung Cancer . Wendi S Lee, MSN, RN, NP-C. Anne ...
NA_00092076/ J1414, Protocol Version 4.8 Dated 13November2018
NA_00092076/ J1414, Protocol Version 4.8 Dated 13November2018
by singh
1 Study Title: Neoadjuvant Nivolumab, or Nivoluma...
Presented at the European Society for Medical Oncology 2019 Barcelona
Presented at the European Society for Medical Oncology 2019 Barcelona
by lucy
– 1 October, 2019 ● GSK 3377794 activate and i...
Mechanisms of ALK Resistance & Implications for Treatment
Mechanisms of ALK Resistance & Implications for Treatment
by evans
Robert C. Doebele, MD, PhD. Associate Professor, ....
cell lung cancer NSCLCESMO Clinical Practice Guidelines for diagnosi
cell lung cancer NSCLCESMO Clinical Practice Guidelines for diagnosi
by adia
RecommendationLoE, GoRScreening with LDCT (low-dos...
The Winship Cancer Institute of Emory University
The Winship Cancer Institute of Emory University
by jalin
July 22, 2023. Adjuvant immunotherapy for resectab...
Updates in the systemic treatment for lung
Updates in the systemic treatment for lung
by madeline
cancer: Immunotherapy. Oscar Arrieta MD. Thoracic....
FIRST-LINE EGFRm+ NSCLC PATIENT CASE STUDY
FIRST-LINE EGFRm+ NSCLC PATIENT CASE STUDY
by pamela
Case study 9. Provided by . Dr Qamar Ghafoor, Clin...
New developments in oncological treatment for Stage 3 NSCLC
New developments in oncological treatment for Stage 3 NSCLC
by summer
Lung SSG 22. nd. May 2018. Gareth Ayre. Rationale...
Phase II studies of Nivolumab
Phase II studies of Nivolumab
by brianna
in patients with Advanced . Squamous. (SQ) or Non...
Lung Tumors
Lung Tumors
by lorenzo155
4/1/24. Michael Forte, MD. Outline . Lung Cancer ...